{"id":3089,"date":"2021-04-04T10:40:14","date_gmt":"2021-04-04T01:40:14","guid":{"rendered":"https:\/\/www.emukk.com\/WP\/?p=3085"},"modified":"2021-04-04T11:28:43","modified_gmt":"2021-04-04T02:28:43","slug":"using-sars-cov-2-nanoparticles-as-a-vaccine-a-broadly-neutralizing-antibody-strong-to-sars-cov-2-variants-could-be-induced","status":"publish","type":"post","link":"https:\/\/www.emukk.com\/WP\/en\/using-sars-cov-2-nanoparticles-as-a-vaccine-a-broadly-neutralizing-antibody-strong-to-sars-cov-2-variants-could-be-induced\/","title":{"rendered":"Using SARS-CoV-2 nanoparticles as a vaccine, a broadly neutralizing antibody strong to SARS-CoV-2 variants could be induced\u00a0"},"content":{"rendered":"

A group from Scripps Research Institute has reported that a broadly neutralizing antibody strong to SARS-CoV-2 variants could be induced by using SARS-CoV-2 nanoparticles as a vaccine.
\nhttps:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8010731\/<\/a><\/p>\n

The main stream of the current vaccines is using platforms which deliver the recombinant SARS-CoV-2 spike as an antigen such as mRNA-encapsulated liposomes (e.g., BNT162b2 and mRNA-1273), adenovirus vectors (e.g., ChAdOx1 nCoV-19 [AZD1222], CTII-nCoV, Sputnik V, and Ad26.COV2.S). There vaccines are compatible with B.1.1.7 variant, but a notable loss of efficacy was reported for B.1.351 and P.1 variants. Therefore, it is required to develop vaccines that can elicit a broadly neutralizing antibody (bNAb) response to SARS-CoV-2 variants. For this purpose, those vaccines have to induce long-lived germinal center (GC) reactions to activate precursor B cells, stimulate affinity maturation, and form long-term immune memory.<\/p>\n

The SARS-CoV-2 spike protein is a trimer of S1-S2 heterodimers. The S1 subunit contains a receptor-binding domain (RBD) to initiate infection. The S2 subunit consists of a fusion peptide (FP) and heptad repeat regions 1 and 2 (HR1 and HR2). Authors designed an HR2-deleted glycine-capped spike (S2G\u0394HR2) to increase the spike stability, and assembled those spikes on a nanoparticle platform called SApNP using I3\u201301v9 60-mers as a linker (S2G\u0394HR2-10GS-I3-01v9-LD7-PADRE (I3-01v9-L7P)). The I3\u201301v9-LP7 presents 20 stabilized spikes.<\/p>\n

Using S2G\u0394HR2-10GS-I3-01v9-L7P as a vaccine, a bNAb were induced showing compatible titers for B.1.1.7, B.1.351, and P.1 variants. Compared with the soluble spike, this nanoparticle showed 6-fold longer retention, 4-fold greater presentation on follicular dendritic cell dendrites, and 5-fold higher germinal center reactions in lymph node follicles. The reason of this effect is not clear yet, but would be related to the size effect.<\/p>\n

\"\"<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

A group from Scripps Research Institute has reported that a broadly neutralizing antibody strong to SARS-CoV-2<\/p><\/div>\n

\u7d9a\u304d\u3092\u8aad\u3080<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-3089","post","type-post","status-publish","format-standard","hentry","category-technology-en"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t